30th week of 2018 patent applcation highlights part 22 |
Patent application number | Title | Published |
20180208489 | METHOD FOR DETECTING AND CONTROLLING THE AMOUNT OF CATIONIC SPECIES IN A WATER STREAM - A method for detecting and controlling the amount of cationic species in a water stream in accordance with embodiments of the present disclosure is carried out by adding a solution containing a pre-determined quantity of a fluorescent tracer to the sample of water stream to obtain a solution comprising a complex. The fluorescence emission spectra of the solution is measured for detecting the presence or absence of the cationic species based on the attenuation and shift of the emission peak in the range of 640 nm to 655 nm. | 2018-07-26 |
20180208490 | ENERGY HYDROGEN WATER DISSOLVING DEVICE - Disclosed is an energy hydrogen water dissolving device that passes a clean water source through a pressurized pump. A part of the water is sent to a hydrogen production equipment and decomposed into hydrogen and oxygen, and the other part of the water is driven to an energy hydrogen water dissolving and storage tank. The oxygen formed by the hydrogen production equipment is discharged to the outside or returned to the clean water source, and the hydrogen formed by the hydrogen production equipment is connected and sent to an input end of the pressurized pump, pressurized and mixed uniformly by the pressurized pump and outputted to the clean water, so that the water liquid entering into the energy hydrogen water dissolving and storage tank becomes high dissolution hydrogen water. The energy hydrogen water dissolving and storage tank contains an energy mineral, a hydrogen molecule mineral and a terminal filter, and the water liquid discharged from the energy hydrogen water dissolving and storage tank is formed into healthy drinking water with tiny water molecules, weak alkaline, high negative potential and high dissolution hydrogen molecules | 2018-07-26 |
20180208491 | METHOD FOR TREATING AMMONIACAL NITROGEN IN WASTEWATER - Provided is a method for treating ammoniacal nitrogen in wastewater performed via biologically oxidizing ammoniacal nitrogen, and producing nitrite nitrogen and nitrate nitrogen at a desired rate. In the method, ammoniacal nitrogen is oxidized by bacterial sludges to produce at least either of nitrite nitrogen and nitrate nitrogen. Specifically, the method includes an inactivating treatment step of treating the bacterial sludges with an inactivating operation via sterilizing bacteria or causing bacteriostasis, and a nitrifying treatment step of oxidizing the ammoniacal nitrogen by the bacterial sludges thus treated in the inactivating operation. Production amounts of the nitrite nitrogen and the nitrate nitrogen are controlled by adjusting biomass of the bacterial sludges to be treated in the inactivating operation, and/or a time interval between the inactivating operations each repeatedly performed in combination with the nitrifying treatment step. | 2018-07-26 |
20180208492 | LARGE MELTING KILN SUITABLE FOR BOROSILICATE GLASS - A large melting furnace suitable for borosilicate glass. Which has a melting area, a reinforcing area, an ascending area and a clarifying area. The melting area and the reinforcing area are separated by a partition wall, and a lower end of the partition wall goes deep below a surface of molten glass but is not in contact with a bottom of the melting furnace, so as to guarantee that the molten glass in the two areas is interconnected. The structures of the melting area and reinforcing area can also improve the problem of boron volatilization of the borosilicate glass caused by flame melting during a melting process. The molten glass flows out from a throat of the reinforcing area, passes through the ascending area and enters the shallower clarifying area. | 2018-07-26 |
20180208493 | BOTTLE WITH VENTED NECK - A glass bottle includes a body having a closed end, a shoulder spaced from the end, a neck extending from the shoulder, and a neck finish at an end of the neck for attachment of a closure, characterized in that the neck finish and at least a portion of the neck adjacent to the neck finish have non-circular internal surfaces. | 2018-07-26 |
20180208494 | TRIM ELEMENT FOR INTERIOR VEHICLE - The invention relates to a trim element for interior vehicle. According to the invention, the trim element is made of glass sheet. | 2018-07-26 |
20180208495 | HIGH-TRANSPARENCY GLASS - The present invention provides a high-transparency glass having a high fining action at a low temperature and capable of achieving redox lowering more than before. The present invention relates to a glass containing 1 to 500 ppm of a total iron oxide (t-Fe | 2018-07-26 |
20180208496 | BOROSILICATE GLASS FOR PHARMACEUTICAL CONTAINER - A borosilicate glass for a pharmaceutical container includes SiO | 2018-07-26 |
20180208497 | GLASS FIBER, COMPOSITION FOR PRODUCING THE SAME, AND COMPOSITE MATERIAL COMPRISING THE SAME - A composition for producing a glass fiber, including the following components with corresponding percentage amounts by weight: SiO | 2018-07-26 |
20180208498 | Glass Compositions, Fiberizable Glass Compositions, and Glass Fibers Make Therefrom - Embodiments of the present invention provide glass compositions, fiberizable glass compositions, and glass fibers formed from such compositions, as well as glass strands, yarns, fabrics, and composites comprising such glass fibers adapted for use in various applications. In some embodiments of the present invention, the glass compositions additionally include at least one rare earth oxide. | 2018-07-26 |
20180208499 | Glass Compositions, Fiberizable Glass Compositions, and Glass Fibers Made Therefrom - New glass compositions and applications thereof are disclosed. Embodiments of the present invention relate to glass compositions, to fiber glass strands, to chopped fiber glass strands, to nonwoven mats of glass fibers, and to other products and methods. A fiber glass strand comprises a plurality of glass fibers comprising the glass composition of the present invention. | 2018-07-26 |
20180208500 | GLASS LIGHT GUIDING PLATE - A glass light-guiding plate which has high-temperature stability and is advantageous in being manufactured in a slim profile is provided. The glass light-guiding plate includes a glass plate including 75 to 85 wt % SiO | 2018-07-26 |
20180208501 | LOW TEMPERATURE FLUORIDE GLASSES AND GLAZES - An article comprises a body having a coating. The coating comprising a eutectic system having a super-lattice of a first fluoride and a second fluoride. The coating includes a glaze on a surface of the coating, the glaze comprising the eutectic system having the super-lattice of the first fluoride and the second fluoride. | 2018-07-26 |
20180208502 | COATED ARTICLE WITH LOW-E COATING HAVING ABSORBING LAYERS FOR LOW FILM SIDE REFLECTANCE AND LOW VISIBLE TRANSMISSION - Absorbing layers of a low-emissivity (low-E) coating are designed to cause the coating to have a reduced film side reflectance which is advantageous for aesthetic purposes. In certain embodiments, the absorbing layers are metallic or substantially metallic (e.g., NiCr or NiCrN | 2018-07-26 |
20180208503 | GLASS COMPRISING A FUNCTIONAL COATING CONTAINING SILVER AND INDIUM - A material includes a transparent substrate coated with a stack of thin layers including at least one silver-based functional metal coating, at least two dielectric coatings including at least one dielectric layer, so that each functional metal coating is positioned between two dielectric coatings, wherein the functional metal coating includes at least 1% by weight of indium relative to the weight of silver and indium in the functional metal coating. | 2018-07-26 |
20180208504 | OPTICAL FIBER COATING DIE WITH REDUCED WETTED LENGTH - An optical fiber coating apparatus that provides increased gyre stability and reduced gyre strength, thereby providing a more reliable coating application process during fiber drawing includes a cone-only coating die having a conical entrance portion with a tapered wall angled at a half angle α, wherein 2°≤α≤25°, and a cone height L | 2018-07-26 |
20180208505 | BINDERS AND MATERIALS MADE THEREWITH - Binders to produce or promote cohesion in non-assembled or loosely assembled matter. | 2018-07-26 |
20180208506 | METHOD FOR GRINDING CEMENT CLINKER - Method of grinding cement clinkers comprising at least two kinds of clinker phases with differing grindability. | 2018-07-26 |
20180208507 | HYDRAULIC COMPOSITION - A hydraulic composition comprising an AE agent, water-soluble cellulose ether, defoamer, cement, water, and aggregate is provided. The AE agent contains a fatty acid-based surfactant consisting of a fatty acid, alkali metal salt, lower alkylamine salt or lower alkanolamine salt thereof and a nonionic surfactant consisting of a polyoxyethylene phenyl ether. The hydraulic composition has frost damage resistance and experiences little bleeding. | 2018-07-26 |
20180208508 | PREMIXED HYBRID GROUT - Grouts, grout products and methods of applying such grouts that include a urethane-acrylic hybrid polymer dispersion (UA-HPD) and a filler material. The UA-HPD may be present in an amount of about 10-40% by weight of the composition, while the filler material may be present in an amount of about 60-90% by weight of the composition. Additional filler materials may also be provided within the UA-HPD grout composition to provide the resultant UA-HPD grout with desired characteristics and properties. The UA-HPD containing grouts are applied between spaced-apart tiles and/or masonry to fill voids and/or joints there-between. | 2018-07-26 |
20180208509 | SELF-PRESTRESSED REINFORCED CONCRETE ELEMENTS - The present invention relates to improved concrete elements, particularly to self-prestressed, high-performance concrete elements (SP-HPC elements); to cementitious compositions suitable, for producing such concrete elements; to methods of manufacturing such concrete elements and such cementitious compositions; to the use of specific components in concrete elements and cementitious mixtures. The compositions and elements described herein comprise an effective amount of expansive agents in combination with superabsorbent polymers (SAP) and shrinkage reducing admixtures (SRA), and optional further components as defined in the claims. The present invention further provides for improved tendons, suitable for SP-HPC elements. | 2018-07-26 |
20180208510 | LONG-WORKABILITY CALCIUM ALUMINATE CEMENT WITH HARDENING PROMOTED BY A TEMPERATURE INCREASE, AND RELATED USE - Disclosed is to a calcium aluminate cement, including a calcium aluminate with a first crystallised mineralogical phase of calcium dialuminate CA2 including one calcium oxide CaO for two aluminium oxides Al | 2018-07-26 |
20180208511 | SPARK PLASMA SINTERED POLYCRYSTALLINE DIAMOND - The present disclosure relates a spark plasma sintered polycrystalline diamond and methods of spark plasma sintering leached polycrystalline diamond. Spark plasma sintering produces plasma from a reactant gas found in the pores left by catalyst removal from leached polycrystalline diamond. The plasma forms diamond bonds and/or carbide structures in the pores, which may produce polycrystalline diamond that is has a higher impact strength than the leached polycrystalline diamond or other improved properties. | 2018-07-26 |
20180208512 | COATED CERAMIC PLATE, COUPLING ELEMENTS FOR PAVEMENTS, AND USES THEREOF - The present description relates to a ceramic plate having a polymer coating, and obtaining methods and uses of the ceramic plate. The polymer coating of the ceramic plate can comprise at least one polymer and up to 30% (m/m) of hollow glass microspheres having a size inferior to 90 microns. The ceramic plate can further include a crosslinking agent or an adhesion promoting agent, or a mixture of these agents. The ceramic plate allows for the reduction of a cold feeling. In order to reduce cold feeling, the present description further relates to ceramic coating plates with printed and encapsulated heating elements. The coating plates can be interconnected between plates by means of coupling elements. | 2018-07-26 |
20180208513 | FERTILIZER COMPOSITION AND METHODS OF MAKING AND USING SAME - In accordance with the present invention, disclosed herein is a fertilizer core particle and fertilizer granule. The fertilizer core particle has one or more fertilizer additives, one or more binders comprising a wax, and one or more pH buffering agents, and wherein the core particle comprises from about 10 wt % to about 99 wt % of the one or more binders comprising a wax. | 2018-07-26 |
20180208514 | COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF NUTRIENTS AND MICRONUTRIENTS TO PLANTS - Compounds, including chelated compounds, which may be used for the delivery of nutrients and micronutrients to plants are provided. In addition, processes for preparing such compounds, compositions comprising such compounds, and methods for delivering nutrients and micronutrients to plants with such compounds are provided. | 2018-07-26 |
20180208515 | EQUIPMENT FOR OBTAINING SOLUBLE HUMATE MATERIALS FROM MINERAL COAL - The invention describes an installation, which serves for obtaining humate materials from mineral coal base material, and is provided with raw material depository ( | 2018-07-26 |
20180208516 | ANTICAKING COMPOSITIONS FOR SOLID FERTILIZERS, COMPRISING QUATERNARY ESTER AMMONIUM COMPOUNDS - Anticaking compositions for solid fertilizers comprising quaternary ester ammonium compounds, the use thereof, methods of preparing solid fertilizers resistant to caking and solid fertilizers obtained thereby. | 2018-07-26 |
20180208517 | ANTI-FUNGAL SEED TREATMENT FORMULATIONS, TREATED SEEDS, AND METHODS - A coated seed comprises a seed and a coating at least partially surrounding the seed. The coating comprises a fungicide, a micronutrient metal, and a chelating agent, the fungicide comprising copper (II) hydroxide, wherein the amount of copper (II) hydroxide is from about 0.05 mg/seed to about 0.21 mg/seed. | 2018-07-26 |
20180208518 | SEEDING FORMULATION FOR WOODY PLANTS AND PRE-TREATMENT OF LAND SURFACES - The present disclosure provides a seeding formulation for woody plants and a pre-treatment of surfaces (e.g. rocks, waste rocks, tailings, overburden) on disturbed and degraded lands. The seeding formulation includes a mix of woody trees or shrubs seeds, organic mulch, beneficial microbial populations, mineral fertilizer, adhesive, absorbent polymer, and water. The pre-treatment of surfaces refers to the spreading or mixing of surfaces with organic biomass. Methods of preparing and applying the seeding formulation and pre-treatment are also disclosed. The formulation is used for the phytoremediation, ecological restoration, land reclamation, environmental rehabilitation, revitalization, revegetation, and reforestation of disturbed and degraded lands. | 2018-07-26 |
20180208519 | FERTILIZER COMPOSITION AND METHODS OF MAKING AND USING SAME - In accordance with the present invention, disclosed herein is a fertilizer core and fertilizer granule and methods related thereto. The fertilizer core particle has an outer surface and comprising one or more fertilizer additives, one or more binders, and one or more pH buffering agents, and wherein the fertilizer core particle comprises from about 10 wt % to about 99 wt % of the one or more binders. | 2018-07-26 |
20180208520 | COMPOSITION CONTAINING N-(N-BUTYL) THIOPHOSPHORIC TRIAMIDE ADDUCTS AND REACTION PRODUCTS - Reaction products and methods for making and using such reaction products are provided. For example, a reaction product comprising an adduct formed from two or more of a first nucleophile (e.g., including, but not limited to, a urease inhibitor), a second nucleophile, and an electrophile is described, which can be provided in various forms. Such a reaction product can be in the form of a solid or solution. Such a reaction product can also be combined with one or more additional components, including but not limited to, free urease inhibitor and/or a nitrogen-based fertilizer composition. | 2018-07-26 |
20180208521 | CAST EXPLOSIVE COMPOSITION - The invention relates to a cast explosive composition, particularly to a pre-cure castable explosive composition comprising an explosive material, a polymerisable binder, a microencapsulated cross linking reagent, said microencapsulated cross linking reagent, comprising a cross linking agent encapsulated in a microcapsule. | 2018-07-26 |
20180208522 | TANTALUM-BASED CATALYST DEPOSITED ON SILICA FOR THE TRANSFORMATION OF ETHANOL INTO BUTADIENE - The invention concerns a catalyst comprising at least the element tantalum, and at least one mesoporous oxide matrix that has undergone an acid wash comprising at least 90% by weight of silica before washing, the mass of the element tantalum being in the range 0.1% to 30% of the mass of said mesoporous oxide matrix. | 2018-07-26 |
20180208523 | Production of Aromatics from Methanol Using Selective Hydrogen Combustion - A catalyst system and processes for combined aromatization and selective hydrogen combustion of oxygenated hydrocarbons are disclosed. The catalyst system contains at least one aromatization component and at least one selective hydrogen combustion component. The process is such that the yield of hydrogen is less than the yield of hydrogen when contacting the hydrocarbons with the aromatization component alone. | 2018-07-26 |
20180208524 | MULTIPLE-STAGE CATALYST SYSTEM FOR SELF-METATHESIS WITH CONTROLLED ISOMERIZATION AND CRACKING - Embodiments of processes and multiple-stage catalyst systems for producing propylene comprising introducing a hydrocarbon stream comprising 2-butene to an isomerization catalyst zone to isomerize the 2-butene to 1-butene, passing the 2-butene and 1-butene to a metathesis catalyst zone to cross-metathesize the 2-butene and 1-butene into a metathesis product stream comprising propylene and C | 2018-07-26 |
20180208525 | PROCESS FOR THE OXIDATIVE COUPLING OF METHANE - The invention relates to a process for the oxidative coupling of methane comprising converting methane to one or more C2+ hydrocarbons in a reactor, wherein said process comprises contacting a reactor feed comprising methane and oxygen with a catalyst composition and wherein the linear gas velocity of said reactor feed in the region above the catalyst bed is at least 0.6 m/s, the linear gas velocity through the catalyst bed is at least 0.6 m/s and the partial pressure of oxygen in the reactor is greater than 0.08 MPa. | 2018-07-26 |
20180208526 | MULTIPLE-STAGE CATALYST SYSTEMS AND PROCESSES FOR PROPENE PRODUCTION - Processes and multiple-stage catalyst systems are disclosed for producing propene by at least partially isomerizing butene in an isomerization reaction zone having an isomerization catalyst to form an isomerization reaction product, at least partially metathesizing the isomerization reaction product in a metathesis reaction zone having a metathesis catalyst to form a metathesis reaction product, and at least partially cracking the metathesis reaction product in a cracking reaction zone having a cracking catalyst. The isomerization catalyst may be MgO, and the metathesis catalyst may be a mesoporous silica catalyst support impregnated with a metal oxide. The metathesis reaction zone may be downstream of the isomerization reaction zone, and the cracking reaction zone may be downstream of the metathesis reaction zone. | 2018-07-26 |
20180208527 | DUAL CATALYST PROCESSES AND SYSTEMS FOR PROPYLENE PRODUCTION - Processes and multiple-stage catalyst systems are disclosed for producing propylene from butene by at least partially metathesizing butene in a metathesizing reaction zone having a metathesis catalyst to form a metathesis reaction product and at least partially cracking the metathesis reaction product in a cracking reaction zone having a cracking catalyst to form a cracking reaction product that includes propylene. The metathesis catalyst may be a mesoporous silica-alumina catalyst support impregnated with metal oxide having a mesoporous silica-alumina catalyst support comprising from 5 weight percent to 50 weight percent alumina. The cracking catalyst may be a MFI structured silica-containing catalyst. The cracking reaction zone may be downstream of the metathesis reaction zone. | 2018-07-26 |
20180208528 | PROCESS FOR THE CO-PRODUCTION OF 2,3,3,3-TETRAFLUOROPROPENE AND 1,3,3,3-TETRAFLUOROPROPENE - The present invention provides a method of producing 2,3,3,3-tetrafluoropropene (HFO-1234yf), wherein the method comprises two or more reaction steps, at least one of said reaction steps comprising the production of 1,3,3,3-tetrafluoropropene (HFO-1234ze) and/or one or more HFO-1234ze precursors from one or more HFO-1234yf precursors, wherein at least a portion of the HFO-1234ze is recovered. | 2018-07-26 |
20180208529 | SERIAL METHANOL REACTORS - The present relates to a process comprising the steps of Providing a syngas stream with module M to a Methanol loop, In the Methanol loop passing the syngas though a first Methanol reactor, obtaining a first effluent from the first Methanol reactor, Cooling the first effluent and condensing at least part of the produced methanol Separating the first cooled effluent into at least a first raw Methanol stream and a first unreacted stream, Heating the first unreacted stream, Passing the first heated unreacted stream through a second methanol reactor, Obtaining a second effluent from the second methanol reactor, Separating the second effluent into at least a second raw Methanol stream and a second unreacted stream, and Recycling the second unreacted stream to the syngas stream. | 2018-07-26 |
20180208530 | PROCESS FOR THE SYNTHESIS OF 9,9-BIS(HYDROXYMETHYL)FLUORENE - The present invention relates to a novel process for the synthesis of 9,9-bis(hydroxymethyl)fluorene. The syntheses from fluorene to 9,9-bis(hydroxymethyl)fluorene via a hydroxymethylation and further to 9,9-bis(methoxymethyl)fluorene via a etherification are known. 9,9-bis(methoxymethyl)fluorene is a compound that is used as an electron donor for Ziegler-Natta catalysts. The present invention is related to an improvement in the synthesis of 9,9-bis(hydroxymethyl)fluorene leading to a decrease in the amount of solvent used and an easier work up while achieving high yield and purity. | 2018-07-26 |
20180208531 | FLUORENE-CONTAINING COMPOUND AND METHOD FOR MAKING THE SAME - A fluorene-containing compound having a formula (I) | 2018-07-26 |
20180208532 | PROCESS FOR PREPARING AN ARYLPROPENE - A process for preparing an arylpropene from a diarylpropane by gas phase thermolysis in the presence of boron containing zeolitic material comprising a membered ring (MR) pore system greater than 10 MR. | 2018-07-26 |
20180208533 | PROCESS FOR PREPARING AN ARYLPROPENE - A process for preparing an arylpropene from a diarylpropane by gas phase thermolysis in the presence of solid porous catalyst comprising silica having large pore volume and low acidity. | 2018-07-26 |
20180208534 | METHOD FOR PROVIDING A SUCCINIC ACID SOLUTION - The invention pertains to a method for providing a succinic acid solution, comprising the steps of—providing a first magnesium succinate containing medium with a magnesium succinate concentration of 18-23 wt. % to a first acidification reactor where it is contacted with hydrogen chloride to form a solution of succinic acid, magnesium chloride and hydrogen chloride,—providing a second magnesium succinate containing medium with a magnesium | 2018-07-26 |
20180208535 | PROCESS FOR THE COUPLED PRODUCTION OF SWEET WHEY AND LACTIC ACID FROM ACID WHEY - A process for the coupled production of sweet whey and lactic acid from acid whey is suggested, comprising the following steps:
| 2018-07-26 |
20180208536 | Elucidation of Novel 13-Series Resolvins that Increase with Atorvastatin and Clear Infections - Endogenous mechanisms leading to host protection and resolution of infections without immunosuppression are of wide interest. Here we elucidated the structures of four new host-protective molecules produced in neutrophil-endothelial co-cultures, and present in human and mouse tissues after sterile inflammation or infection. These bioactive molecules contained conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and were derived from n-3 docosapentaenoic acid (DPA, C22:5). These compounds, termed 13-series resolvins (RvT), demonstrated potent protective actions increasing mice survival during | 2018-07-26 |
20180208537 | PROCESS FOR MAKING ESTERS OF 2-ACETOXYALKANOIC ACIDS USING A 3,6-DIALKYL-1,4-DIOXANE-2,5-DIONE OR POLY-(ALPHA-HYDROXYALKANOIC ACID) AS A STARTING MATERIAL - 2-Acetoxyalkanoic acid esters are made in a reaction of a 3,6-dialkyl-1,4-dioxane-2,5-dione or a poly(α-hydroxyalkanoic acid), an acetate ester and an alcohol or phenol in the presence of a transesterification catalyst. Unlike previous methods for making 2-acetoxyalkanoic acid esters, this process proceeds in high yield and high selectivity to the desired product. | 2018-07-26 |
20180208538 | INFLUENCING THE VISCOSITY OF N-BUTENE-BASED ESTER MIXTURES BY CONTROLLED USE OF ETHENE IN THE PREPARATION OF THE ESTER PRECURSORS - The invention relates to a process for preparing an ester mixture, in which an n-butene-containing feed mixture having a composition which changes over time is first oligomerized and then converted by hydroformylation, hydrogenation and esterification to an ester mixture. In this process, an approximation of the actual viscosity of the ester mixture is determined. The problem that it addresses is that of specifying a comparatively simple process which enables conversion of an n-butene with a variable composition over time to an ester mixture having a viscosity which can be kept very substantially constant over a long period even when an inconstant C | 2018-07-26 |
20180208539 | METHODS FOR PRODUCING ALKYL HYDROXYALKANOATES - Methods and systems for producing alkyl hydroxyalkanoate from hydroxy carboxylic acid recovery bottoms. The methods generally comprise the steps of obtaining a hydroxy carboxylic acid recovery bottom, adding a mono-alcohol to the hydroxy carboxylic acid recovery bottom to obtain a first mixture, heating the first mixture in the presence of a catalyst to form a reaction product, distilling the reaction product, and recovering an alkyl hydroxyalkanoate fraction. | 2018-07-26 |
20180208540 | FRUITY ODORANT - The present invention concerns the use as perfuming ingredient (of the fruity type) of a compound of formula | 2018-07-26 |
20180208541 | DIISOPENTYL TEREPHTHALATE - A mixture of isomeric dipentyl terephthalates, pentyl radicals of which are n-pentyl radicals to an extent of less than 60 mol %, characterized by a low viscosity which does not increase significantly even at temperatures below 40° C. Plastisols comprising these mixtures have a low plastisol viscosity which moreover increases only to a minor degree with time. | 2018-07-26 |
20180208542 | METHOD FOR PREPARING SELEGILINE BASE - The present invention relates to a process for the preparation of selegiline base, an irreversible and selective inhibitor of the MAO-B enzymes and which is used in the treatment of Parkinson's Disease. | 2018-07-26 |
20180208543 | NEW METHOD FOR SYNTHESIS OF FENFLURAMINE, AND NEW COMPOSITIONS COMPRISING IT - A new process for preparing the fenfluramine molecule and new compositions containing fenfluramine obtainable with the claimed process. | 2018-07-26 |
20180208544 | AN IMPROVED PROCESS FOR THE PREPARATION OF BACLOFEN AND ITS INTERMEDIATE - The present invention provides an improved process for the preparation of 3-(4-chlorophenyl)-3-cyanopropanoic acid (compound (A)) and further its transformation to Baclofen (I). The process comprises reaction of compound (II) with Glyoxylic acid to obtain 3-(4-chlorophenyl)-3-cyanoacrylic acid (III); followed by the ‘in-situ’ reduction of (III) in the presence of a reducing agent to provide the compound (A). Alternatively, the compound (A) is obtained by the process comprising reacting 2-(4-chlorophenyl)acetonitrile (II) with haloacetic acid (IV) in the presence of a base. The compound 3-(4-chlorophenyl)-3-cyanopropanoic acid (A) undergoes hydrogenation in the presence of a metal catalyst and ammonia solution to provide Baclofen (I). | 2018-07-26 |
20180208545 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY - The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA. | 2018-07-26 |
20180208546 | METHOD FOR MAKING A PRENYL GROUP-SUBSTITUTED TYROSINE COMPOUND - A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed. | 2018-07-26 |
20180208547 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - Here described is a method of delivery of a drug to a stellate cell using a composition comprising a compound of formula I: | 2018-07-26 |
20180208548 | HIGH PURITY HCN FROM ACRYLONITRILE CO-PRODUCTION - Disclosed is a process for co-manufacture of ACRN and HCN with improved HCN selectivity and reduced solids formation in a shared product recovery section. | 2018-07-26 |
20180208549 | NEW TYPE OF ANTIVIRAL COMPOUND - Provided are a new aromatic cyanogen compound and a preparation method thereof. The present invention also relates to the use of such compound in antiviral drugs, in particular the use thereof in anti-HCV drugs. | 2018-07-26 |
20180208550 | METHOD FOR PRODUCING A CYCLIC ISOCYANATE - The present invention relates to a process for preparing a cyclic isocyanate (B) from a composition (Z) which comprises at least one component (A) which has at least one cycloalkane ring having at least 4 ring carbons, where the cycloalkane ring has two NH | 2018-07-26 |
20180208551 | METHOD FOR PRODUCING ORGANIC UREA AND THE ORGANIC UREA AND AUS32 THEREBY OBTAINED - A method for producing organic urea is provided that, by mixing and reacting liquid ammonia (NH | 2018-07-26 |
20180208552 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF - The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like. | 2018-07-26 |
20180208553 | A PROCESS FOR PRODUCING TAURINE - The present application provides a process for preducing taurine, comprising the steps as follows: (a) mixing isethionic acid with taurine salt solution until the system pH reaches a certain value in a range from 5.0 to 9.5; (b) separating liquid phase and solid phase of the system; wherein said solid phase is the crude product of taurine, and said liquid phase is isethionate solution; (c) reacting ammonia solution with said liquid phase obtained from step (b) to obtain taurine salt solution. It uses isethionic acid to adjust the pH of the taurine salt solution, avoiding the problem causing by using sulphate acid to adjust the pH in the traditional process. By the recycling use of the cations in taurine salts, a new raw material or reagent does not need to be added which is benefit to reducing the use of dangerous chemical materials, simplifying the production process greatly, improving the utilization rate of raw materials, increasing the yield of the product and decreasing production cost significantly. | 2018-07-26 |
20180208554 | Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof - Compounds that inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease. | 2018-07-26 |
20180208555 | METHOD OF SYNTHESIS OF AN IONIZABLE CATIONIC LIPID - What is described is a method of synthesis of the compound of formula 1A, | 2018-07-26 |
20180208556 | Method for Preparing Pimavanserin - Provided is a method for preparing pimavanserin including reacting an intermediate compound represented by Formula (II) with N-(4-fluorobenzyl)-1-methylpiperidin-4-amine or a salt thereof, or reacting an intermediate compound represented by Formula (IV) with 4-isobutoxybenzylamine or a salt thereof, wherein L represents a heteroaryl group, —OR | 2018-07-26 |
20180208557 | PHENYL-CYANOQUINOLINONE PDE9 INHIBITORS - The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. | 2018-07-26 |
20180208558 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM - The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease. | 2018-07-26 |
20180208559 | PROCESS FOR THE PREPARATION OF 3-HALOALKYLPYRAZOLES - A process for the preparation of a compound of formula IX: | 2018-07-26 |
20180208560 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof - The present invention relates to compounds of formula I, | 2018-07-26 |
20180208561 | QUINOXALINE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF - A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) | 2018-07-26 |
20180208562 | Selective Sulfonation of Benzodiazepine Derivatives - The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention. | 2018-07-26 |
20180208563 | THERMODYNAMICALLY STABLE CRYSTAL MODIFICATION OF 2-CHLORO-3-(METHYLSULFANYL)-N-(1-METHYL-1H-TETRAZOL-5-YL)-4-(TRIFLUOROMET- HYL)BENZAMIDE - Thermodynamically stable crystal modification of 2-chloro-3-(methylsulfanyl)-N-(1-methyl-1H-tetrazol-5-yl)-4-(trifluoromethyl)benzamide | 2018-07-26 |
20180208564 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS - Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity. | 2018-07-26 |
20180208565 | METHODS OF CHEMICAL SYNTHESIS OF SUBSTITUTED 10H-PHENOTHIAZINE-3,7-DIAMINE COMPOUNDS - The present invention pertains generally to the field of chemical synthesis, and more particularly to methods of chemical synthesis which include the step of preparing a substituted 10H-phenothiazine-3,7-diamine compound of Formula (1) by a step of selective alkylation by reductive amination, in which the corresponding unsubstituted diamine of Formula (4) is reacted with aldehyde/ketone, under reductive amination conditions. The present invention also relates to such methods which incorporate additional subsequent and/or preceding steps, for example, to prepare compounds of Formulae (2) and (3) from compounds of Formula (1), and to prepare compounds of Formula (4) from, for example, compounds of Formulae (5), (6), (7), (8), and (9). Compounds of Formula (1), Formula (2), and Formula (3) are useful, for example, in the treatment of diseases of protein aggregation, such as Alzheimer's disease. | 2018-07-26 |
20180208566 | Deuterated Meclizine - This invention relates to deuterated forms of meclizine, and pharmaceutically acceptable salts or hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering meclizine and other Constitutive Androstane Receptor agonists or FGFR3 antagonists. | 2018-07-26 |
20180208567 | PROCESS FOR MAKING HYDROXYETHYL PIPERAZINE COMPOUNDS - The present invention relates to an improved process for making hydroxyethyl piperazine compounds especially mono-hydroxyethyl piperazine. The improvement comprises reacting piperazine and an alkylene oxide, preferably ethylene oxide in a reactive distillation column. | 2018-07-26 |
20180208568 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME - This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition. | 2018-07-26 |
20180208569 | LIQUID PHASE SELECTIVE OXIDATION TO EPOXIDES WITH MOLECULAR OXYGEN - The present disclosure relates to a method for effecting catalytic selective oxidation in liquid phase comprising a perfluorinated solvent and an olefinic compound with molecular oxygen to produce an epoxide. The method may provide enhanced selectivity to the epoxide of greater than 60%. The olefinic compound may be ethylene, propylene, butenes, 1-octene, butadiene, allyl chloride, allyl alcohol, styrene, and the like. The perfluorinated solvent may be perfluoro methyldecalin, perfluorodecalin, perfluoroperhydrophenanthrene, perfluoro (butyltetrahydrofuran), isomers thereof, or a combination thereof. In some embodiments, the method includes catalytically epoxidizing, in a liquid phase comprising a perfluorinated solvent, propylene with molecular oxygen to produce propylene oxide. A system for carrying out the method is also provided, the system comprising a source of a perfluorinated solvent, and a liquid phase reactor fluidly connected with the source, and configured for effecting catalytic selective oxidation, in a liquid phase comprising the perfluorinated solvent, of an olefinic compound with molecular oxygen to produce an epoxide. | 2018-07-26 |
20180208570 | BIS-FURAN DERIVATIVES AS TRANSTHYRETIN (TTR) STABILIZERS AND AMYLOID INHIBITORS FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY (FAP) - The design and synthesis of a novel bis-furan scaffold tailored for high efficiency at inhibiting transthyretin amyloid formation is reported. In vitro results show that the discovered compounds are more efficient inhibitors of amyloid formation than tafamidis, a drug currently used in the treatment of familial amyloid polyneuropathy (FAP), despite their lower molecular weight and lipophilicity. Moreover, ex vivo experiments with the strongest inhibitor in the series, conducted in human blood plasma from normal and FAP Val30Met-transthyretin carriers, disclose remarkable affinity and selectivity profiles. The promises and challenges facing further development of this compound are discussed under the light of increasing evidence implicating transthyretin stability as a key factor not only in transthyretin amyloidoses and several associated co-morbidities, but also in Alzheimer's disease. | 2018-07-26 |
20180208571 | Method for Obtaining Vitamin E, Sterols and/or Terpenes From Oily or Fatty Mixtures of Biological Origin - Disclosed is a continuous process for concentrating or separating of vitamin E, sterols and/or terpenes from oily or fatty mixtures of biological origin comprising the measures:
| 2018-07-26 |
20180208572 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME - Described herein are Δ | 2018-07-26 |
20180208573 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF - Disclosed are compounds, for example, compounds of formula (I), (Formula (I) wherein R, R | 2018-07-26 |
20180208574 | PRO-DRUGS AND RELATED METHODS - The invention relates to Pro-drugs, comprising red-ox-sensitive cleavage sites. The compounds may be utilized in medical practice for targeting of si RNA, antisense oligonucleotides or protein-based therapeutics to the cytoplasmatic compartment of cells both in vitro or in vivo, in a subject in need. | 2018-07-26 |
20180208575 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA | 2018-07-26 |
20180208576 | NOVEL SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 - The present invention relates to novel selective | 2018-07-26 |
20180208577 | Compounds and Methods of Use - This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies. | 2018-07-26 |
20180208578 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) - The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. | 2018-07-26 |
20180208579 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2018-07-26 |
20180208580 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF - Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A. | 2018-07-26 |
20180208581 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF - The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases. | 2018-07-26 |
20180208582 | COMPOUNDS, COMPOSITIONS, AND METHODS - The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof. | 2018-07-26 |
20180208583 | OXIME ESTER PHOTOINITIATORS - Compounds of the formulae (I) or (II) | 2018-07-26 |
20180208584 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS - Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity. | 2018-07-26 |
20180208585 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF - The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exon19 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives. | 2018-07-26 |
20180208586 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS - There are provided compounds, their preparation and their use in the treatment of medical conditions including cancers and immune disorders. | 2018-07-26 |
20180208587 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE - The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds. | 2018-07-26 |
20180208588 | HETEROCYCLIC COMPOUNDS AND USE THEREOF - Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation, and for treating tissue injury, cancer, inflammatory disease, and autoimmune disease. | 2018-07-26 |